CC-99712 for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called CC-99712 for people with multiple myeloma, a type of blood cancer, who have tried other treatments without success. The study will assess the safety and effectiveness of CC-99712 when administered alone or with another drug, BMS-986405. Individuals with multiple myeloma that recurs or resists treatment might be suitable for this trial. Participants will receive the treatment through an IV (intravenous infusion) and will continue until the disease progresses or they choose to stop. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that CC-99712 is still undergoing safety testing in humans. This Phase 1 trial marks the first time this treatment is being tested in people. During this phase, researchers aim to determine the correct dose and monitor for any side effects.
Currently, there is limited information on how well people tolerate CC-99712 alone. Since this is its first human trial, the primary goal is to establish a safe dose and observe participant responses.
Safety data on the combination of CC-99712 with BMS-986405 is also limited. The trial examines how these drugs interact and what side effects may arise.
In Phase 1 trials like this, safety remains uncertain. Researchers seek to learn more about potential side effects and how to manage them. Participating in a trial at this stage contributes to gathering crucial safety information.12345Why are researchers excited about this trial's treatments?
Researchers are excited about CC-99712 for multiple myeloma because it introduces a new approach to treatment. Unlike traditional therapies such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, CC-99712 is administered via intravenous infusion and may offer a unique mechanism of action. In one treatment arm, CC-99712 is combined with BMS-986405, an oral medication, potentially enhancing its effectiveness. This combination could provide a dual approach to tackle the disease more effectively than current options. The innovation in both delivery and combination could lead to more effective treatment outcomes for patients with multiple myeloma.
What evidence suggests that this trial's treatments could be effective for multiple myeloma?
Research shows that CC-99712, one of the treatments in this trial, has promising results for people with multiple myeloma when used alone. In earlier studies, 60% of patients responded positively, with some even achieving complete remission, meaning no signs of cancer were found.
This trial will also study the combination of CC-99712 with another drug, BMS-986405. Studies for this combination are ongoing. CC-99712 specifically targets and attacks cancer cells, potentially making it a strong option for treating this condition. The focus is on how well these treatments can target multiple myeloma cells and improve patient outcomes.23467Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults over 18 with multiple myeloma that has come back or hasn't responded to treatment. They must have measurable disease and be in good physical condition (ECOG PS of 0 or 1). It's not for pregnant women, those with HIV, brain involvement of MM, recent stem cell transplants, or active hepatitis B/C.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of CC-99712 to determine the maximum tolerated dose (MTD)
Dose Expansion
Participants receive CC-99712 at or below the MTD to evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CC-99712
Find a Clinic Near You
Who Is Running the Clinical Trial?
Celgene
Lead Sponsor
Jay Backstrom
Celgene
Chief Medical Officer since 2016
MD
Mark Alles
Celgene
Chief Executive Officer since 2016
Bachelor's degree from Lock Haven University of Pennsylvania